{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:04:37Z","timestamp":1780074277916,"version":"3.54.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40119-026-00447-7","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:55:32Z","timestamp":1777488932000},"page":"171-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trimetazidine's Anti-ischemic Effectiveness in Patients with Stable Angina with Prior Myocardial Infarction Evaluated via Stress Echocardiography with Speckle Tracking: METHOD study"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05210465","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0806-7061","authenticated-orcid":false,"given":"Boris B.","family":"Kvasnikov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4642-3610","authenticated-orcid":false,"given":"Olga L.","family":"Barbarash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7458-6962","authenticated-orcid":false,"given":"Olga M.","family":"Polikutina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5379-7258","authenticated-orcid":false,"given":"Yuriy P.","family":"Burtsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"13_Supplement","key":"447_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(24)04310-9","volume":"83","author":"B Stark","year":"2024","unstructured":"Stark B, Johnson C, Roth G. Global prevalence of coronary artery disease: an update from the Global Burden of Disease Study. JACC. 2024;83(13_Supplement):2320.","journal-title":"JACC"},{"issue":"9","key":"447_CR2","doi-asserted-by":"publisher","first-page":"6110","DOI":"10.15829\/1560-4071-2024-6110","volume":"29","author":"OL Barbarash","year":"2024","unstructured":"Barbarash OL, Karpov YA, Panov AV, et al. 2024 Clinical practice guidelines for Stable coronary artery disease. Russ J Cardiol. 2024;29(9):6110.","journal-title":"Russ J Cardiol."},{"issue":"7","key":"447_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.121.054567","volume":"144","author":"J Mesnier","year":"2021","unstructured":"Mesnier J, Ducrocq G, Danchin N, CLARIFY Investigators, et al. International observational analysis of evolution and outcomes of chronic stable angina: the multinational CLARIFY Study. Circulation. 2021;144(7):512\u201323.","journal-title":"Circulation."},{"key":"447_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ahj.2016.02.015","volume":"175","author":"A Shafiq","year":"2016","unstructured":"Shafiq A, Arnold SV, Gosch K, et al. Patient and physician discordance in reporting symptoms of angina among stable coronary artery disease patients: Insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study. Am Heart. 2016;175:94\u2013100.","journal-title":"Am Heart"},{"issue":"36","key":"447_CR5","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, ESC Scientific Document Group, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415\u2013537 (Erratum in: Eur Heart J. 2025 Apr 22;46(16):1565).","journal-title":"Eur Heart J"},{"key":"447_CR6","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1161\/01.CIR.102.10.1158","volume":"102","author":"S Urheim","year":"2000","unstructured":"Urheim S, Edvardsen T, Torp H, et al. Myocardial strain by Doppler echocardiography. Validation of new method to quantify regional myocardial function. Circulation. 2000;102:1158\u201364.","journal-title":"Circulation"},{"issue":"3","key":"447_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233\u201370.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"447_CR8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0735-1097(03)00789-7","volume":"42","author":"JP Curtis","year":"2003","unstructured":"Curtis JP, Sokol SI, Wang Y, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol. 2003;42(4):736\u201342.","journal-title":"J Am Coll Cardiol"},{"key":"447_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.mayocp.2018.07.017","volume":"94","author":"SA Luis","year":"2019","unstructured":"Luis SA, Chan J, Pellikka PA. Echocardiographic assessment of left ventricular systolic function: an overview of contemporary techniques, including speckle-tracking echocardiography. Mayo Clin Proc. 2019;94:125\u201338.","journal-title":"Mayo Clin Proc"},{"key":"447_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2011.01.015","volume":"24","author":"V Mor-Avi","year":"2011","unstructured":"Mor-Avi V, Lang RM, Badano LP. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE\/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr. 2011;24:277\u2013313.","journal-title":"J Am Soc Echocardiogr"},{"key":"447_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ihj.2012.12.004","volume":"65","author":"M Bansal","year":"2013","unstructured":"Bansal M, Kasliwal R. How do I do it? Speckle-tracking echocardiography. Indian Heart J. 2013;65:117\u201323.","journal-title":"Indian Heart J"},{"issue":"4","key":"447_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/ehjcvp\/pvv051","volume":"2","author":"CP McCarthy","year":"2016","unstructured":"McCarthy CP, Mullins KV, Kerins DM. The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent. Eur Heart J Cardiovasc Pharmacothery. 2016;2(4):266\u201372.","journal-title":"Eur Heart J Cardiovasc Pharmacothery"},{"issue":"3","key":"447_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1365-2125.1994.tb04276.x","volume":"37","author":"JM Detry","year":"1994","unstructured":"Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol. 1994;37(3):279\u201388.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 4","key":"447_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/BF00051292","volume":"4","author":"S Dalla-Volta","year":"1990","unstructured":"Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther. 1990;4(Suppl 4):853\u20139.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"447_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2165\/00129784-200303050-00007","volume":"3","author":"P Sellier","year":"2003","unstructured":"Sellier P, Broustet JP. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am J Cardiovasc Drugs. 2003;3(5):361\u20139.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"447_CR16","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ijcard.2012.11.001","volume":"68","author":"C Vitale","year":"2013","unstructured":"Vitale C, Spoletini I, Malorni W, Perrone-Filardi P, Volterrani M, Rosano GMC. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina--the VASCO-angina study. Int J Cardiol. 2013;68(2):1078\u201381.","journal-title":"Int J Cardiol"},{"key":"447_CR17","first-page":"144","volume":"22","author":"H Baminger","year":"2015","unstructured":"Baminger H. Treatment of stable angina in Ukraine: CLASSICA study. J Kardiol. 2015;22:144\u20135.","journal-title":"J Kardiol"},{"issue":"2","key":"447_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1157\/13072496","volume":"205","author":"L Rodr\u00edguez Padial","year":"2005","unstructured":"Rodr\u00edguez Padial L, Maicas Bellido C, Vel\u00e1zquez Mart\u00edn M, Gil Polo B. A prospective study on trimetazidine effectiveness and tolerability in diabetic patients in association to the previous treatment of their coronary disease. DIETRIC study. Rev Clin Esp. 2005;205(2):57\u201362.","journal-title":"Rev Clin Esp"},{"key":"447_CR19","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/eurheartj\/ehi816","volume":"27","author":"G Fragasso","year":"2006","unstructured":"Fragasso G, Perseghin G, De Cobelli F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine\/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006;27:942\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehi816.","journal-title":"Eur Heart J"},{"key":"447_CR20","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/hrt.2011.226332","volume":"97","author":"G Fragasso","year":"2011","unstructured":"Fragasso G, Salerno A, Lattuada G, et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart. 2011;97:1495\u2013500.","journal-title":"Heart"},{"key":"447_CR21","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1161\/CIRCULATIONAHA.108.778019","volume":"118","author":"H Tuunanen","year":"2008","unstructured":"Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008;118:1250\u20138.","journal-title":"Circulation"},{"key":"447_CR22","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S0002-9149(98)00500-1","volume":"82","author":"C Lit","year":"1998","unstructured":"Lit C, Dabrovski P, Fragasso G, Chierchia SL. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. The Am J Of Cardiol. 1998;82:898\u2013901.","journal-title":"The Am J Of Cardiol"},{"issue":"12","key":"447_CR23","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480. (Epub 2023 Sep 26. Erratum in: J Hypertens. 2024 Jan 1;42(1):194. doi: 10.1097\/HJH.0000000000003621. PMID: 37345492.).","journal-title":"J Hypertens"},{"issue":"1","key":"447_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.17816\/brmma25960","volume":"22","author":"AN Kuchmin","year":"2020","unstructured":"Kuchmin AN, Yaroslavtsev MY, Afendikov NV, et al. Evaluation of the antiischemic effect of a prolonged form of trimetazidine in patients with stable angina pectoris using speckle-tracking technique. Bull Russ Mil Med Acad. 2020;22(1):18\u201322.","journal-title":"Bull Russ Mil Med Acad"},{"key":"447_CR25","unstructured":"Cohen J. Statistical power analysis for the Behavioral Sciences (1988, 2nd ed.). Routledge, ISBN-10 0805802835; ISBN-13 978\u20130805802832"},{"issue":"4","key":"447_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5582\/ddt.2022.01020","volume":"16","author":"RP Harjoko","year":"2022","unstructured":"Harjoko RP, Sobirin MA, Uddin I, et al. Trimetazidine improves left ventricular global longitudinal strain value in patients with heart failure with reduced ejection fraction due to ischemic heart disease. Drug Discov Ther. 2022;16(4):177\u201384.","journal-title":"Drug Discov Ther"},{"issue":"Supplement_1","key":"447_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.831","volume":"5","author":"Y Rustamova","year":"2024","unstructured":"Rustamova Y, Imanov G, Azizov V. The effect of trimetazidine on the left ventricular global longitudinal strain assessed by cardiac magnetic resonance in stable angina patients with previous myocardial infarction and left ventricular. Eur Heart J. 2024;5(Supplement_1):ehae666.831.","journal-title":"Eur Heart J"},{"issue":"36","key":"447_CR28","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, ESC Scientific Document Group, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726 (Erratum in: Eur Heart J. 2021 Dec 21;42(48):4901).","journal-title":"Eur Heart J"},{"key":"447_CR29","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895\u20131032.","journal-title":"Circulation"},{"key":"447_CR30","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789\u2013858.","journal-title":"Lancet"},{"issue":"17","key":"447_CR31","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2022","unstructured":"Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2022;118(17):3272\u201387.","journal-title":"Cardiovasc Res"},{"issue":"11","key":"447_CR32","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.15829\/1560-4071-2024-6162","volume":"29","author":"AS Galyavich","year":"2024","unstructured":"Galyavich AS, Tereshchenko SN, Uskach TM, et al. Chronic heart failure. Clinical guidelines 2024. Russian J Cardiol. 2024;29(11):6162. https:\/\/doi.org\/10.15829\/1560-4071-2024-6162","journal-title":"Russian J Cardiol"},{"issue":"20","key":"447_CR33","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1161\/CIRCULATIONAHA.106.645184","volume":"114","author":"H Tuunanen","year":"2006","unstructured":"Tuunanen H, Engblom E, Naum A, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation. 2006;114(20):2130\u20137.","journal-title":"Circulation"},{"issue":"24","key":"447_CR34","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1053\/euhj.2001.2896","volume":"22","author":"H Szwed","year":"2001","unstructured":"Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II) TRIMetazidine in POLand. Eur Heart J. 2001;22(24):2267\u201374.","journal-title":"Eur Heart J"},{"issue":"1","key":"447_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00045391-200501000-00006","volume":"12","author":"EI Chazov","year":"2005","unstructured":"Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazidine in angina combination therapy\u2013the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther. 2005;12(1):35\u201342.","journal-title":"Am J Ther"},{"key":"447_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40119-021-00249-z","volume":"11","author":"Y Lopatin","year":"2022","unstructured":"Lopatin Y, Petrova P, the MODUS VIVENDI investigators. Effectiveness and tolerability of trimetazidine 80\u00a0Mg once daily in patients with stable angina uncontrolled with bisoprolol-based therapy: the modus vivendi observational study. Cardiol Ther. 2022;11:93\u2013111.","journal-title":"Cardiol Ther"},{"issue":"4","key":"447_CR37","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s12325-017-0490-2","volume":"34","author":"M Glezer","year":"2017","unstructured":"Glezer M, CHOICE-2 study investigators. Real-world evidence for the antianginal efficacy of trimetazidine from\u00a0the\u00a0Russian observational CHOICE-2 Study. Adv Ther. 2017;34(4):915\u201324.","journal-title":"Adv Ther"},{"issue":"9","key":"447_CR38","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1007\/s12325-018-0756-3","volume":"35","author":"MG Glezer","year":"2018","unstructured":"Glezer MG, Vygodin VA, ODA investigators. Anti-anginal effectiveness and tolerability of trimetazidine modified release 80\u00a0Mg once daily in stable angina patients in real-world practice. Adv Ther. 2018;35(9):1368\u201377.","journal-title":"Adv Ther"},{"issue":"10","key":"447_CR39","doi-asserted-by":"publisher","first-page":"1161993","DOI":"10.3389\/fcvm.2023.1161993","volume":"26","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li Y, Zhu L, Xu J, Tang X, Gao P. Blood pressure control and left ventricular echocardiographic progression in hypertensive patients: an 18-month follow-up study. Front Cardiovasc Med. 2023;26(10):1161993.","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"447_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11906-017-0777-3","volume":"19","author":"EZ Soliman","year":"2017","unstructured":"Soliman EZ, Prineas RJ. Antihypertensive therapies and left ventricular hypertrophy. Curr Hypertens Rep. 2017;19(10):79.","journal-title":"Curr Hypertens Rep"},{"issue":"12","key":"447_CR41","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1097\/HJH.0000000000000340","volume":"32","author":"S Cheng","year":"2014","unstructured":"Cheng S, Shah AM, Albisu JP, et al. Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease. J Hypertens. 2014;32(12):2479\u201386.","journal-title":"J Hypertens."},{"key":"447_CR42","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/echo.15625","volume":"40","author":"M Kornev","year":"2023","unstructured":"Kornev M, Caglayan HA, Kudryavtsev AV, et al. Influence of hypertension on systolic and diastolic left ventricular function including segmental strain and strain rate. Echocardiography. 2023;40:623\u201333.","journal-title":"Echocardiography"},{"issue":"10","key":"447_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2261-10-4","volume":"18","author":"M Ugander","year":"2010","unstructured":"Ugander M, Cain PA, Johnsson P, Palmer J, Arheden H. Chronic non-transmural infarction has a delayed recovery of function following revascularization. BMC Cardiovasc Disord. 2010;18(10):4.","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00447-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00447-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00447-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:41:26Z","timestamp":1780072886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00447-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["447"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00447-7","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Olga L. Barbarash declares providing consultancy services, participation in advisory boards, research and speaker activities for Novartis, Sanofi, Servier, and Nizhpharm pharmaceutical companies. Olga M. Polikutina declares no conflict of interest. Boris B. Kvasnikov is an employee of Servier Russia. Yuriy P. Burtsev was by the time of the manuscript development an employee of Servier Russia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. The study protocol was approved by the Inter-academic Ethics Committee (Moscow, Russia) on November 25, 2021, protocol #10. Informed consent for medical record review and the use of research-related health information was obtained in accordance with local regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}